Ilona Farr
Family Medicine · Anchorage, AKNPI 1306944095
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 487 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 487 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$2K
- GSK$1K
- Novo Nordisk$1K
- Amgen$681
- Lilly USA, LLC$635
- plus $5K from 28 others
What the payments were for
- Food & beverage$14,04599%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 107 | $3,206 |
| AbbVie(2 entities) | 93 | $2,228 |
| GSK | 46 | $1,379 |
| Novo Nordisk | 44 | $1,334 |
| Amgen(2 entities) | 11 | $681 |
| Lilly USA, LLC | 26 | $635 |
| Novartis | 12 | $605 |
| Merck | 28 | $519 |
| Pfizer | 24 | $483 |
| Astellas Pharma US Inc | 11 | $384 |
| Boehringer Ingelheim | 8 | $349 |
| Antares Pharma, Inc. | 1 | $323 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $261 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $228 |
| Genentech USA, Inc. | 6 | $163 |
| Medtronic | 3 | $147 |
| Exact Sciences | 6 | $141 |
| Biohaven Pharmaceuticals, Inc. | 8 | $135 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Eisai Inc. | 7 | $108 |
| Amarin Pharma, Inc. | 6 | $101 |
| Regeneron Healthcare Solutions, Inc. | 1 | $83 |
| Kowa Pharmaceuticals America, Inc. | 3 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Nestle Healthcare Nutrition Inc. | 3 | $71 |
| Johnson & Johnson | 4 | $67 |
| Kyowa Kirin, Inc. | 1 | $64 |
| Bayer | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $40 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Scynexis, Inc. | 1 | $31 |
| Corcept Therapeutics | 1 | $21 |
| Pharming Healthcare, Inc. | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,165 in reported general payments places this provider in the 95th percentile of 334 family medicine providers in Alaska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $40,938 |
| EliquisApixaban | 18 | $25,000 |
| OzempicSemaglutide | 22 | $24,005 |
| JanuviaSitagliptin Phosphate | 13 | $21,404 |
| MounjaroTirzepatide | 20 | $20,920 |
| SynthroidLevothyroxine Sodium | 69 | $7,816 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 49 | $5,649 |
| Valsartan | 71 | $2,454 |
| Estradiol | 19 | $2,103 |
| ValacyclovirValacyclovir Hcl | 35 | $1,842 |
| Fluconazole | 33 | $1,541 |
| Rosuvastatin Calcium | 84 | $1,441 |
| Duloxetine Hcl | 25 | $1,384 |
| Sumatriptan Succinate | 14 | $1,140 |
| Ezetimibe | 43 | $1,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $349 | $40,93827 claims |
| PfizerEliquis | $483 | $25,00018 claims |
| Novo NordiskOzempic | $1,334 | $24,00522 claims |
| MerckJanuvia | $519 | $21,40413 claims |
| Lilly USA, LLCMounjaro | $635 | $20,92020 claims |
| AbbVieSynthroid | $2,228 | $7,81669 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 family medicine providers in Alaska.
Other family medicine in Anchorage
- Mary FolandAnchorage$15K
- Eric MiknichAnchorage$13K
- Allison KelliherAnchorage$6K
- Bruce KiesslingAnchorage$5K
- Kathryn RyanAnchorage$5K
- Bruck CliftAnchorage$5K
- Ulyana StiassnyAnchorage$4K
- Pebbles ShanleyAnchorage$4K
- Kenneth MollAnchorage$3K
- Jane SimonoAnchorage$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.